|
1
|
Liang Y, Wang L, Zhu Y, Lin Y, Liu H, Rao
H, Xu G and Rong T: Primary pulmonary lymphoepithelioma-like
carcinoma: Fifty-two patients with long-term follow-up. Cancer.
118:4748–4758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He J, Shen J, Pan H, Huang J, Liang W and
He J: Pulmonary lymphoepithelioma-like carcinoma: A Surveillance,
Epidemiology and end results database analysis. J Thorac Dis.
7:2330–2338. 2015.PubMed/NCBI
|
|
3
|
Lin Z, Situ D, Chang X, Liang W, Zhao M,
Cai C, Liu Y and He J: Surgical treatment for primary pulmonary
lymphoepithelioma-like carcinoma. Interact Cardiovasc Thorac Surg.
23:41–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin CY, Chen YJ, Hsieh MH, Wang CW and
Fang YF: Advanced primary pulmonary lymphoepithelioma-like
carcinoma: Clinical manifestations, treatment, and outcome. J
Thorac Dis. 9:123–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lv YL, Yuan DM, Wang K, Miao XH, Qian Q,
Wei SZ, Zhu XX and Song Y: Diagnostic performance of integrated
positron emission tomography/computed tomography for mediastinal
lymph node staging in non-small cell lung cancer: A bivariate
systematic review and meta-analysis. J Thorac Oncol. 6:1350–1358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan HY, Tsoi A, Wong MP, Ho JC and Lee
EY: Utility of 18F-FDG PET/CT in the assessment of
lymphoepithelioma-like carcinoma. Nucl Med Commun. 37:437–445.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aktas GE, Can N, Demir SS and Sarikaya A:
Primary pulmonary lymphoepithelioma-like carcinoma on FDG PET/CT.
Nucl Med Mol Imaging. 51:88–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su TP, Ho KC, Wang CW, Lin CY, Liu CY,
Yang CT and Yen TC: Prognostic value and clinical impact of
pretreatment FDG PET in pulmonary lymphoepithelioma-like carcinoma.
Clin Nucl Med. 44:e68–e75. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tateishi U, Gamez C, Dawood S, Yeung HW,
Cristofanilli M and Macapinlac HA: Bone metastases in patients with
metastatic breast cancer: Morphologic and metabolic monitoring of
response to systemic therapy with integrated PET/CT. Radiology.
247:189–196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu J, Khong PL, Wang S, Chan Q, Law W and
Zhang J: Quantitative assessment of diffusion-weighted MR imaging
in patients with primary rectal cancer: Correlation with
FDG-PET/CT. Mol Imaging Biol. 13:1020–1028. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen HH, Chiu NT, Su WC, Guo HR and Lee
BF: Prognostic value of whole-body total lesion glycolysis at
pretreatment FDG PET/CT in non-small cell lung cancer. Radiology.
264:559–566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paesmans M, Berghmans T, Dusart M, Garcia
C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M,
Scherpereel A, et al: Primary tumor standardized uptake value
measured on fluorodeoxyglucose positron emission tomography is of
prognostic value for survival in non-small cell lung cancer: Update
of a systematic review and meta-analysis by the European Lung
Cancer Working Party for the International Association for the
Study of Lung Cancer Staging Project. J Thorac Oncol. 5:612–619.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hayashi T, Haba R, Tanizawa J, Katsuki N,
Kadota K, Miyai Y, Bando K, Shibuya S, Nakano M and Kushida Y:
Cytopathologic features and differential diagnostic considerations
of primary lymphoepithelioma-like carcinoma of the lung. Diagn
Cytopathol. 40:820–825. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang YL, Wu CT, Shih JY and Lee YC: New
aspects in clinicopathologic and oncogene studies of 23 pulmonary
lymphoepithelioma-like carcinomas. Am J Surg Pathol. 26:715–723.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ngan RK, Yip TT, Cheng WW, Chan JK, Cho
WC, Ma VW, Wan KK, Au SK, Law CK and Lau WH: Circulating
Epstein-Barr virus DNA in serum of patients with
lymphoepithelioma-like carcinoma of the lung: A potential surrogate
marker for monitoring disease. Clin Cancer Res. 8:986–994.
2002.PubMed/NCBI
|
|
16
|
Beasley MB, Brambilla E and Travis WD: The
2004 World Health Organization classification of lung tumors. Semin
Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldstraw P: The 7th edition of TNM in
lung cancer: What now? J Thorac Oncol. 4:671–673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hung CY, Lin TL, Kuo YC, Hsieh CH, Wang HM
and Hsu CL: Progesterone analogues reduce plasma Epstein-Barr virus
DNA load and improve pain control in recurrent/metastatic
nasopharyngeal carcinoma patients under supportive care. Biomed J.
40:212–218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsu CL, Chang KP, Lin CY, Chang HK, Wang
CH, Lin TL, Liao CT, Tsang NM, Lee LY, Chan SC, et al: Plasma
Epstein-Barr virus DNA concentration and clearance rate as novel
prognostic factors for metastatic nasopharyngeal carcinoma. Head
Neck. 34:1064–1070. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khiewvan B, Ziai P, Houshmand S, Salavati
A, Ziai P and Alavi A: The role of PET/CT as a prognosticator and
outcome predictor in lung cancer. Expert Rev Respir Med.
10:317–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang KP, Tsang NM, Liao CT, Hsu CL, Chung
MJ, Lo CW, Chan SC, Ng SH, Wang HM and Yen TC: Prognostic
significance of 18F-FDG PET parameters and plasma Epstein-Barr
virus DNA load in patients with nasopharyngeal carcinoma. J Nucl
Med. 53:21–28. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han AJ, Xiong M and Zong YS: Association
of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the
lung in southern China. Am J Clin Pathol. 114:220–226. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma BB, King A, Lo YM, Yau YY, Zee B, Hui
EP, Leung SF, Mo F, Kam MK, Ahuja A, et al: Relationship between
pretreatment level of plasma Epstein-Barr virus DNA, tumor burden
and metabolic activity in advanced nasopharyngeal carcinoma. Int J
Radiat Oncol Biol Phys. 66:714–720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang W, Chen Y, Chen L, Guo R, Zhou G,
Tang L, Mao Y, Li W, Liu X, Du X, et al: The clinical utility of
plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma:
The dawn of a new era? A systematic review and meta-analysis of
7836 cases. Medicine (Baltimore). 94:e8452015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ngan RK, Yip TT, Cheng WW, Chan JK, Cho
WC, Ma VW, Wan KK, Au JS and Law CK: Clinical role of circulating
Epstein-Barr virus DNA as a tumor marker in lymphoepithelioma-like
carcinoma of the lung. Ann N Y Acad Sci. 1022:263–270. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Davies A, Tan C, Paschalides C, Barrington
SF, O'Doherty M, Utley M and Treasure T: FDG-PET maximum
standardised uptake value is associated with variation in survival:
Analysis of 498 lung cancer patients. Lung Cancer. 55:75–78. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu J, Dong M, Sun X, Li W, Xing L and Yu
J: Prognostic Value of 18F-FDG PET/CT in surgical non-small cell
lung cancer: A meta-analysis. PLoS One. 11:e01461952016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen T, Tang LQ, Luo DH, Chen QY, Li PJ,
Mai DM, Guo SS, Liu LT, Qian CN, Guo X, et al: Different prognostic
values of plasma Epstein-Barr virus DNA and maximal standardized
uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma
patients with recurrence. PLoS One. 10:e01227562015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soret M, Bacharach SL and Buvat I:
Partial-volume effect in PET tumor imaging. J Nucl Med. 48:932–945.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hoang JK, Hoagland LF, Coleman RE, Coan
AD, Herndon JE II and Patz EF Jr: Prognostic value of fluorine-18
fluorodeoxyglucose positron emission tomography imaging in patients
with advanced-stage non-small-cell lung carcinoma. J Clin Oncol.
26:1459–1464. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Obara P and Pu Y: Prognostic value of
metabolic tumor burden in lung cancer. Chin J Cancer Res.
25:615–622. 2013.PubMed/NCBI
|
|
33
|
Lee P, Bazan JG, Lavori PW, Weerasuriya
DK, Quon A, Le QT, Wakelee HA, Graves EE and Loo BW: Metabolic
tumor volume is an independent prognostic factor in patients
treated definitively for non-small-cell lung cancer. Clin Lung
Cancer. 13:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Soussan M, Chouahnia K, Maisonobe JA,
Boubaya M, Eder V, Morere JF and Buvat I: Prognostic implications
of volume-based measurements on FDG PET/CT in stage III
non-small-cell lung cancer after induction chemotherapy. Eur J Nucl
Med Mol Imaging. 40:668–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Loon J, Offermann C, Ollers M, van
Elmpt W, Vegt E, Rahmy A, Dingemans AM, Lambin P and De Ruysscher
D: Early CT and FDG-metabolic tumour volume changes show a
significant correlation with survival in stage I–III small cell
lung cancer: A hypothesis generating study. Radiother Oncol.
99:172–175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chung HW, Lee KY, Kim HJ, Kim WS and So Y:
FDG PET/CT metabolic tumor volume and total lesion glycolysis
predict prognosis in patients with advanced lung adenocarcinoma. J
Cancer Res Clin Oncol. 140:89–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang D, Zhang M, Gao X and Yu L:
Prognostic value of baseline 18F-FDG PET/CT functional parameters
in patients with advanced lung adenocarcinoma stratified by EGFR
mutation status. PLoS One. 11:e01583072016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang XY, Zhao YF, Liu Y, Yang YK, Zhu Z
and Wu N: Comparison of different automated lesion delineation
methods for metabolic tumor volume of 18F-FDG PET/CT in patients
with stage I lung adenocarcinoma. Medicine (Baltimore).
96:e93652017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carlier T and Bailly C: State-Of-The-Art
and recent advances in quantification for therapeutic Follow-Up in
oncology using PET. Front Med (Lausanne). 2:182015.PubMed/NCBI
|
|
40
|
Adams MC, Turkington TG, Wilson JM and
Wong TZ: A systematic review of the factors affecting accuracy of
SUV measurements. AJR Am J Roentgenol. 195:310–320. 2010.
View Article : Google Scholar : PubMed/NCBI
|
